Sakar Healthcare's record carries a clear contradiction at its centre: exchange filings repeatedly certify zero financial indebtedness while its own annual reports disclose secured bank borrowings, and the gap between the two has never been reconciled. The profit record is better than the debt picture, operating cash flow has consistently exceeded reported profit, but capital is being sunk into a plant whose completion keeps slipping, and the company has never paid a dividend.
Key findings
- Exchange filings say zero debt; annual reports show secured bank loans
Major- Six financial results filed between 8 Feb 2025 and 24 Jul 2026 each state total financial indebtedness of ₹0 crore. The FY2025-26 annual report discloses a secured SBI loan of ₹31.46 crore, and the FY2024-25 report shows a term loan of ₹53.99 crore plus a working capital loan of ₹39.00 crore. A ₹300 crore borrowing authorization under Section 180(1)(c) was approved at the FY2019-20 AGM, and promoter unsecured loans were disclosed in 2023. - Capitalised R&D, a growing MAT credit, and boilerplate disclosures shape reported profit
Major- Product development spending was capitalised into "Other Intangible Assets" in FY2025-26, amortised over 3-5 years. The MAT credit entitlement grew to 9.56 crore from 9.03 crore, and management exercised "significant judgment" in recognising it. The FY2020-21 segment note described the company as "primarily engaged in one business segment, namely developing Electronic Manufacturing Cluster," contradicting the pharmaceutical business described in the same filing. - Cash flow beats profit, but the plant keeps slipping and no dividend has ever been paid
Major- CFO/PAT ran between 1.62x and 2.61x annually across FY22-FY26, with FY26 CFO of ₹49.26 crore against PAT of ₹30.48 crore. Management said in Q2 FY27 that ₹27 crore of H1 capex includes ₹17 crore of CWIP, called it "the final capex," and simultaneously said "CapEx requirement is nil". No dividend was recommended in any year from FY2019-20 through FY2025-26. - Promoter loans are disclosed, and one was converted into equity
Minor- Managing Director Sanjay S. Shah converted his non-interest bearing unsecured loan of ₹7,88,40,000 into 6,57,000 equity shares at ₹120 per share on 27 February 2021. Unsecured loans from the two promoter-directors were disclosed for the half-year ended 30 September 2023. The FY2025-26 Board's Report states all related party transactions were at arm's length with none material, and CARO confirmed compliance with sections 177 and 188. - One dormant subsidiary, but annual reports contradicted themselves on whether it exists
Minor- Sakar Oncology Private Limited, incorporated 29 March 2020, has been the only subsidiary since FY2020, with nil assets, nil revenue and nil cash outflows as at 31 March 2025. The FY2023 MD&A states "The Company has no subsidiary" on one page and discloses the subsidiary on another. The same contradiction appears in the FY2022, FY2020 and FY2019 reports. - Secretarial auditor resigned mid-engagement; statutory auditor has been stable
Minor- M/s. Nishant Pandya & Associates resigned as Secretarial Auditors with immediate effect from FY2025-26 due to personal reasons, announced 6 May 2026. M/s. Kashyap R. Mehta & Partners was appointed in casual vacancy. Statutory auditor M/s. J S Shah & Co. has held office since the 18th AGM for FY2022-23 to FY2026-27, and CARO confirms no statutory auditor resignation in FY2025-26. - Operating cash flow has consistently backed reported profit
Clean- CFO/PAT ran between 1.62x and 2.61x annually across FY22-FY26. ROCE improved from 8.41% in FY2024-25 to 12.54% in FY2026. Free cash flow was ₹1.75 crore in FY2024-25, after a negative ₹35.09 crore in FY2024.
What to watch
- Next quarterly filing. The stated "total financial indebtedness of ₹0 crore" can be checked against the secured SBI loan of ₹31.46 crore in the FY2025-26 annual report.
- CWIP capitalisation. Whether the ₹17 crore of CWIP disclosed in Q2 FY27 gets completed and capitalised, against management's "final capex" claim.
- Half-yearly RPT disclosure. The next Regulation 23(9) filing for the half-year ending 30 September 2026, following the pattern of 6 November 2023.
- R&D split quantification. Whether future filings quantify capitalised versus expensed product development spend, after the unquantified Q2 FY27 disclosure.
- ICRA rating action. The 22 September 2025 rating of [ICRA] BBB (Positive) / A3+ may reflect actual debt versus exchange-filing disclosures.
Bottom line: This is a company whose cash generation is real and consistently exceeds reported profit, with a stable auditor and pledge-free promoter holding. The risk sits in the debt picture: exchange filings say zero, annual reports say otherwise, and the gap has never been explained. Watch the next quarterly filing for the first reconciliation, and the CWIP line for whether the promised "final capex" actually lands.